Ferguson Wellman Capital Management Inc buys $33,574,822 stake in Amgen (AMGN)

Amgen (AMGN) : Ferguson Wellman Capital Management Inc scooped up 1,238 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 206,069 shares of Amgen which is valued at $33,574,822.Amgen makes up approximately 1.37% of Ferguson Wellman Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Arcadia Investment Management Corpmi boosted its stake in AMGN in the latest quarter, The investment management firm added 128 additional shares and now holds a total of 178 shares of Amgen which is valued at $29,002. Amgen makes up approx 0.01% of Arcadia Investment Management Corpmi’s portfolio.Physicians Financial Services boosted its stake in AMGN in the latest quarter, The investment management firm added 1,050 additional shares and now holds a total of 9,465 shares of Amgen which is valued at $1,542,132. Amgen makes up approx 1.31% of Physicians Financial Services’s portfolio.Mai Capital Management reduced its stake in AMGN by selling 8,810 shares or 10.6% in the most recent quarter. The Hedge Fund company now holds 74,325 shares of AMGN which is valued at $12,109,772. Amgen makes up approx 0.97% of Mai Capital Management’s portfolio.Curian Capital reduced its stake in AMGN by selling 39,131 shares or 66.38% in the most recent quarter. The Hedge Fund company now holds 19,816 shares of AMGN which is valued at $3,192,358. Amgen makes up approx 0.23% of Curian Capital’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.